Proficient Market Insights Final Logo-01-01.png
Life Reinsurance Market Size In 2022 (New Report) | No. of pages: 115|: Manufacturers Data, Opportunity, Import Export Scenario, Application, Type, Regions and Future Forecast till 2028 with Top Growth Companies
16 nov. 2022 02h12 HE | Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Life Reinsurance Market" research report focus on overall information that can help to take decisions on current market situation. Reinsurance, also known as...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10 nov. 2022 16h00 HE | aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences
10 nov. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
09 nov. 2022 08h00 HE | aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
Atyr_Logo.png
aTyr Pharma to Present at the Jefferies London Healthcare Conference
25 oct. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
11 oct. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...
Atyr_Logo.png
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
04 oct. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
29 sept. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
27 sept. 2022 08h00 HE | aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
WWW_logo_black_transparent-1.png
Experience a Pirate’s Life in Multiplayer Arcade Brawler Plunder Panic, Out Now With Crossplay Between All Major Consoles and Windows PC/Mac
16 sept. 2022 10h00 HE | Will Winn Games
EAST LANSING, Mich., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ahoy, Me Hearties! Hoist the Jolly Roger and sharpen those cutlasses, as Will Winn Games’ pirate-themed online multiplayer brawler Plunder...